These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9216524)

  • 1. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome.
    Toro JR; Stoll HL; Stomper PC; Oseroff AR
    J Am Acad Dermatol; 1997 Jul; 37(1):58-67. PubMed ID: 9216524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
    Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
    Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
    Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
    Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factor analysis in mycosis fungoides/Sézary syndrome.
    Diamandidou E; Colome M; Fayad L; Duvic M; Kurzrock R
    J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):914-24. PubMed ID: 10365922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.
    Alberti-Violetti S; Talpur R; Schlichte M; Sui D; Duvic M
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e105-12. PubMed ID: 25817937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
    Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
    Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
    J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.
    Scarisbrick JJ; Prince HM; Vermeer MH; Quaglino P; Horwitz S; Porcu P; Stadler R; Wood GS; Beylot-Barry M; Pham-Ledard A; Foss F; Girardi M; Bagot M; Michel L; Battistella M; Guitart J; Kuzel TM; Martinez-Escala ME; Estrach T; Papadavid E; Antoniou C; Rigopoulos D; Nikolaou V; Sugaya M; Miyagaki T; Gniadecki R; Sanches JA; Cury-Martins J; Miyashiro D; Servitje O; Muniesa C; Berti E; Onida F; Corti L; Hodak E; Amitay-Laish I; Ortiz-Romero PL; Rodríguez-Peralto JL; Knobler R; Porkert S; Bauer W; Pimpinelli N; Grandi V; Cowan R; Rook A; Kim E; Pileri A; Patrizi A; Pujol RM; Wong H; Tyler K; Stranzenbach R; Querfeld C; Fava P; Maule M; Willemze R; Evison F; Morris S; Twigger R; Talpur R; Kim J; Ognibene G; Li S; Tavallaee M; Hoppe RT; Duvic M; Whittaker SJ; Kim YH
    J Clin Oncol; 2015 Nov; 33(32):3766-73. PubMed ID: 26438120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
    Kim YH; Bishop K; Varghese A; Hoppe RT
    Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients.
    Lebowitz E; Geller S; Flores E; Pulitzer M; Horwitz S; Moskowitz A; Kheterpal M; Myskowski PL
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):108-114. PubMed ID: 30176169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography.
    Tsai EY; Taur A; Espinosa L; Quon A; Johnson D; Dick S; Chow S; Advani R; Warnke R; Kohler S; Hoppe RT; Kim YH
    Arch Dermatol; 2006 May; 142(5):577-84. PubMed ID: 16702495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic imaging in the initial staging of mycosis fungoides and Sézary syndrome.
    Kulin PA; Marglin SI; Shuman WP; Chew DE; Olerud JE
    Arch Dermatol; 1990 Jul; 126(7):914-8. PubMed ID: 2360839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: a single-institution cohort.
    Desai M; Liu S; Parker S
    J Am Acad Dermatol; 2015 Feb; 72(2):276-85. PubMed ID: 25458019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
    Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
    Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.
    Diamandidou E; Colome-Grimmer M; Fayad L; Duvic M; Kurzrock R
    Blood; 1998 Aug; 92(4):1150-9. PubMed ID: 9694702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
    Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
    Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the Sézary syndrome.
    Graham SJ; Sharpe RW; Steinberg SM; Cotelingam JD; Sausville EA; Foss FM
    Cancer; 1993 Aug; 72(3):726-34. PubMed ID: 8334625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system.
    Sausville EA; Worsham GF; Matthews MJ; Makuch RW; Fischmann AB; Schechter GP; Gazdar AF; Bunn PA
    Hum Pathol; 1985 Nov; 16(11):1098-109. PubMed ID: 3876976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells.
    Lyapichev KA; Bah I; Huen A; Duvic M; Routbort MJ; Wang W; Jorgensen JL; Medeiros LJ; Vega F; Craig FE; Wang SA
    Cytometry B Clin Cytom; 2021 Mar; 100(2):183-191. PubMed ID: 32667737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Image-guided lymph node core-needle biopsy predicts survival in mycosis fungoides and Sézary syndrome.
    Calvani J; de Masson A; de Margerie-Mellon C; de Kerviler É; Ram-Wolff C; Gruber A; Meignin V; Brice P; Sadoux A; Mourah S; Bagot M; Battistella M
    Br J Dermatol; 2021 Aug; 185(2):419-427. PubMed ID: 33400272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.